It is NBE-Therapeutics’ vision to become an internationally recognized leader and pioneer for the development of innovative and effective antibody-based medicines. The main focus will be on the development of next-generation Antibody Drug Conjugate (ADCs) products for the treatment of cancer.
In order to achieve this, NBE Therapeutics has developed potent antibody discovery and enzymatic, site-specific toxin-antibody conjugation technologies and plans to utilize these pioneering technologies for the development of a robust therapeutic antibody and ADC drug pipeline.
Value adding collaborations and product licensing will be pursued throughout every stage of company development.
- London, 2019-03-05 - NBE-Therapeutics will present at the 9th World ADC Congress Europe in London
- San Diego, USA, 2019-03-04 - NBE-Therapeutics invited to present at Terrapinn's Americas Antibody Congress
- Basel, 2019-01-29 - Unites States Patent and Trademark Office grants US patent on NBE's linker-toxin technology